Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Want to see KPRX full AI Analyst Report?
Total Valuation
Kiora Pharmaceuticals has a market cap or net worth of $11.70M. The enterprise value is $1.12M.
Market Cap$11.70M
Enterprise Value$1.12M
Share Statistics
Kiora Pharmaceuticals has 4,431,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,431,940
Owned by Insiders2.69%
Owned by Institutions4.02%
Financial Efficiency
Kiora Pharmaceuticals’s return on equity (ROE) is -0.67 and return on invested capital (ROIC) is -40.69%.
Return on Equity (ROE)-0.67
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-40.69%
Return on Capital Employed (ROCE)-0.46
Revenue Per Employee0.00
Profits Per Employee-902.93K
Employee Count12
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kiora Pharmaceuticals is ―. Kiora Pharmaceuticals’s PEG ratio is 0.00200.
PE Ratio―
PS Ratio0.00
PB Ratio0.51
Price to Fair Value0.51
Price to FCF-0.81
Price to Operating Cash Flow-1.06
PEG Ratio0.00200
Income Statement
In the last 12 months, Kiora Pharmaceuticals had revenue of 0.00 and earned -10.84M in profits. Earnings per share was -2.60.
Revenue0.00
Gross Profit-24.80K
Operating Income-9.46M
Pretax Income-12.12M
Net Income-10.84M
EBITDA-9.43M
Earnings Per Share (EPS)-2.60
Cash Flow
In the last 12 months, operating cash flow was -10.42M and capital expenditures -115.81K, giving a free cash flow of -10.53M billion.
Operating Cash Flow-10.42M
Free Cash Flow-10.53M
Free Cash Flow per Share-2.38
Dividends & Yields
Kiora Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-14.01%
50-Day Moving Average2.31
200-Day Moving Average2.33
Relative Strength Index (RSI)61.38
Average Volume (3m)36.18K
Important Dates
Kiora Pharmaceuticals upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 8, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Kiora Pharmaceuticals as a current ratio of 5.99, with Debt / Equity ratio of 2.68%
Current Ratio5.99
Quick Ratio5.99
Debt to Market Cap0.04
Net Debt to EBITDA0.88
Interest Coverage Ratio-473.91
Taxes
In the past 12 months, Kiora Pharmaceuticals has paid -1.28M in taxes.
Income Tax-1.28M
Effective Tax Rate0.11
Enterprise Valuation
Kiora Pharmaceuticals EV to EBITDA ratio is 0.01, with an EV/FCF ratio of 0.01.
EV to Sales0.00
EV to EBITDA0.01
EV to Free Cash Flow0.01
EV to Operating Cash Flow0.01
Balance Sheet
Kiora Pharmaceuticals has $13.87M in cash and marketable securities with $373.59K in debt, giving a net cash position of $13.50M billion.
Cash & Marketable Securities$13.87M
Total Debt$373.59K
Net Cash$13.50M
Net Cash Per Share$3.05
Tangible Book Value Per Share$3.38
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kiora Pharmaceuticals is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.00
Price Target Upside528.27% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-100.00%
EPS Growth Forecast13.00%